ABBV
A bigger AbbVie bag
Farther Finance Advisors decided AbbVie deserved a larger seat at the table, boosting its position by 89.8% and ending up with 90,459 shares worth roughly $20.67 million. That’s the actual headline here: a real-money firm just leaned harder into ABBV.
Why you should care
Institutional buying isn’t a crystal ball, but it can be a clue. When a manager adds this aggressively, it usually means they like the cash flow, the moat, or both — and AbbVie has been giving people plenty to chew on with its latest quarter.
The rest of the story is classic AbbVie
The article also recycles some already-known goodies: AbbVie posted $2.71 in EPS on $16.62 billion in revenue, beating estimates and lifting full-year 2026 guidance to $14.37 to $14.57 in EPS. Oh, and it declared a $1.73 quarterly dividend, which keeps the income crowd smiling — even if the payout ratio is eyebrow-raising enough to make you do a double take.
Big picture
This isn’t a “game-changing” catalyst, but it is a useful signal that at least one institutional investor thinks ABBV is still worth accumulating after a strong run of earnings and guidance chatter. For dividend and healthcare investors, that kind of quiet conviction can matter more than the headline drama.